Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases
March 27, 2025 08:00 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
March 24, 2025 08:31 ET | Source: Sesame

Sesame, America’s Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly’s Obesity Medicine Zepbound

NEW YORK CITY, March 24, 2025 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced a technical integration with...
March 10, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Northstrive Biosciences, Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination
February 27, 2025 13:00 ET | Source: DelveInsight Business Research LLP

WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight

New York, USA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight The WEGOVY market has experienced significant...
February 18, 2025 07:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Pre-Investigational New Drug Meeting Submission Request to U.S. Food and Drug A
February 05, 2025 16:05 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC

- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...
February 04, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio
January 30, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Th
January 24, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right